Clin Oncol | Volume 7, Issue 1 | Research Article | Open Access
Weifang Shao1#, Yanhua Xu1#, Suzhen Lin1*, Junli Gao2, Junshun Gao2 and Hong Wang2*
1Department of Medical Laboratory, Chang Xing People Hospital, China
2Hangzhou Cosmos Wisdom Mass Spectrometry Center, Zhejiang University Medical School, China
#These authors contributed equally to this work
*Correspondance to: Suzhen LinFulltext PDF
Colorectal Cancer (CRC) is one of the most significant neoplasms with high morbidity and mortality. Activation of the Programmed Death protein 1/Programmed Death Ligand 1 (PD-1/PD-L1) signaling pathway results in tumor immune evasion by suppressing the activity of T cells. The correlation of soluble PD-L1 (sPD-L1) in serum/plasma with clinicopathological features, lymph node metastasis, diagnosis and prognosis is less clear. The aim of this study was to investigate the relationship between sPD-L1 and diagnosis potential and clinicopathological features and prognosis of CRC patients. Three hundred patients with CRC were included in this study. sPD-L1 was measured by ELISA. Pretreatment levels of sPD-L1 were significantly elevated in CRC patient
sera compared to healthy donors (P<0.001). The median value of sPD-L1 in healthy donors, CRC with non-lymph node metastasis, and CRC with lymph node metastasis were 246.78 ± 50.2 pg/mL, 284.12 ± 52.7 pg/mL and 321.31 ± 55.3 pg/mL respectively. ROC analysis of sPD-L1 allowed significant differentiation between HC group and CRC group (lymph node metastasis and non lymph node metastasis (AUC=0.861, 95% CI 0.830-0.887, p<0.001). sPD-L1 is a potential biomarker
for the diagnosis of CRC. Multivariate analysis showed that lymph node metastasis and tumor differentiation were independent prognostic factors (all P<0.01), and sPD-L1 was not correlated with the CRC prognosis (p>0.05).
Colorectal cancer; Soluble PD-L1 (sPD-L1); Lymph node metastasis; Diagnosis
Shao W, Xu Y, Lin S, Gao J, Gao J, Wang H. The Diagnosis Value of Soluble Programmed Death-Ligand 1 in Serum from Patients with Colorectal Cancer. Clin Oncol. 2022;7:1937..